ADMA Biologics Inc (NASDAQ:ADMA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of ADMA Biologics Inc (NASDAQ:ADMA) have received an average recommendation of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $18.6667.

Several equities analysts have commented on the stock. Raymond James Financial began coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 target price on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Zacks Research raised shares of ADMA Biologics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, September 2nd. Finally, Mizuho decreased their price objective on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th.

ADMA Biologics Price Performance

ADMA Biologics stock opened at $9.45 on Thursday. The firm has a market cap of $2.12 billion, a PE ratio of 13.50 and a beta of 0.78. The company has a debt-to-equity ratio of 0.49, a current ratio of 6.97 and a quick ratio of 3.81. The stock’s fifty day moving average price is $9.22 and its two-hundred day moving average price is $10.13. ADMA Biologics has a one year low of $7.21 and a one year high of $20.46.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.16. The firm had revenue of $124.39 million during the quarter, compared to the consensus estimate of $125.34 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The company’s revenue was up 2.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.14 EPS. As a group, research analysts expect that ADMA Biologics will post 0.78 EPS for the current fiscal year.

Hedge Funds Weigh In On ADMA Biologics

Several hedge funds and other institutional investors have recently modified their holdings of ADMA. Summit Securities Group LLC bought a new stake in shares of ADMA Biologics during the 4th quarter worth $29,000. iSAM Funds UK Ltd acquired a new stake in ADMA Biologics in the third quarter valued at about $34,000. EverSource Wealth Advisors LLC grew its position in ADMA Biologics by 385.8% in the second quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 2,180 shares during the last quarter. Smartleaf Asset Management LLC grew its position in ADMA Biologics by 28.9% in the second quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 700 shares during the last quarter. Finally, Larson Financial Group LLC raised its stake in ADMA Biologics by 745.1% during the fourth quarter. Larson Financial Group LLC now owns 3,262 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,876 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.